로그인
회원가입
Korean
Korean
English
Chinese
Japanese
Home
Introduction
Contact us
People
PI
Members
Research
Projects
Lab Facility
Publications
Papers
Books
Patents
Photo gallery
Photo gallery
Board
Projet update
Recruiting
Journal club
Home
People
Research
Publications
Photo gallery
Board
Home
Introduction
Contact us
People
PI
Members
Research
Projects
Lab Facility
Publications
Papers
Books
Patents
Photo gallery
Photo gallery
Board
Projet update
Recruiting
Journal club
MOON LAB SNS 바로가기
트위터
페이스북
네이버블로그
MOON LAB
홈페이지 바로가기
MOON LAB
Moon lab pursues development of novel therapeutics for breast, ovary, and prostate cancer
Journal club 글답변
이름
필수
비밀번호
필수
분류
선택하세요
Journal Club
Projet update
HTML
제목
필수
웹에디터 시작
> > > Date: 2021.06.29 > > Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of TNBC > > Zhu et al. Journal of Experimental & Clinical Cancer Research (2021) 40:122 > > Abstract > > Background: PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients with BRCA mutations, and their efficacy is even more limited in triple-negative breast cancer (TNBC) due to clinical primary and acquired resistance. Here, we found that the efficacy of the PARPi olaparib in TNBC can be improved by combination with the CDK4/6 inhibitor (CDK4/6i) palbociclib. > > Methods: We screened primary olaparib-sensitive and olaparib-resistant cell lines from existing BRCAmut/TNBC cell lines and generated cells with acquired olaparib resistance by gradually increasing the concentration. The effects of the PARPi olaparib and the CDK4/6i palbociclib on BRCAmut/TNBC cell lines were examined in both sensitive and resistant cells in vitro and in vivo. Pathway and gene alterations were assessed mechanistically and pharmacologically. > > Results: We demonstrated for the first time that the combination of olaparib and palbociclib has synergistic effects against BRCAmut/TNBC both in vitro and in vivo. In olaparib-sensitive MDA-MB-436 cells, the single agent olaparib significantly inhibited cell viability and affected cell growth due to severe DNA damage. In olaparib-resistant HCC1937 and SUM149 cells, single-agent olaparib was ineffective due to potential homologous recombination (HR) repair, and the combination of olaparib and palbociclib greatly inhibited HR during the G2 phase, increased DNA damage and inhibited tumour growth. Inadequate DNA damage caused by olaparib activated the Wnt signalling pathway and upregulated MYC. Further experiments indicated that the overexpression of β-catenin, especially its hyperphosphorylation at the Ser675 site, activated the Wnt signalling pathway and mediated olaparib resistance, which could be strongly inhibited by combined treatment with Palbociclib. > > Conclusions: Our data provide a rationale for clinical evaluation of the therapeutic synergy of the PARPi olaparib and CDK4/6i palbociclib in BRCAmut/TNBCs with high Wnt signalling activation and high MYC expression that do not respond to PARPi monotherapy. > > *Keywords: Triple-negative breast cancer, PARP inhibitors, CDK4/6 inhibitors, Wnt signalling pathway, Resistance > >
웹 에디터 끝
첨부파일
파일추가
파일삭제
자동등록방지
숫자음성듣기
새로고침
자동등록방지 숫자를 순서대로 입력하세요.
작성완료
취소
전화걸기
문자상담
PL
MEMBERS